NCT06390852

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE2

Sponsor: National Cancer Institute (NCI)

Condition: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.